Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA.

× No keyword cloud information.

10 in total

Review 1. Antibacterial therapy for acute group a streptococcal pharyngotonsillitis: short-course versus traditional 10-day oral regimens.

Authors: Itzhak Brook
Journal: Paediatr Drugs Date: 2002 Impact factor: 3.022

Review 2. Review of macrolides and ketolides: focus on respiratory tract infections.

Authors: G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal: Drugs Date: 2001 Impact factor: 9.546

3. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).

Authors: A L Barry; P C Fuchs; S D Brown
Journal: Antimicrob Agents Chemother Date: 1998-04 Impact factor: 5.191

4. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.

Authors: A L Barry; P C Fuchs; S D Brown
Journal: Eur J Clin Microbiol Infect Dis Date: 1997-10 Impact factor: 3.267

5. Prevalence of polyclonal mefA-containing isolates among erythromycin-resistant group A streptococci in Southern Taiwan.

Authors: J J Yan; H M Wu; A H Huang; H M Fu; C T Lee; J J Wu
Journal: J Clin Microbiol Date: 2000-07 Impact factor: 5.948

6. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.

Authors: D R Feikin; A Schuchat; M Kolczak; N L Barrett; L H Harrison; L Lefkowitz; A McGeer; M M Farley; D J Vugia; C Lexau; K R Stefonek; J E Patterson; J H Jorgensen
Journal: Am J Public Health Date: 2000-02 Impact factor: 9.308

7. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients.

Authors: E Bingen; F Fitoussi; C Doit; R Cohen; A Tanna; R George; C Loukil; N Brahimi; I Le Thomas; D Deforche
Journal: Antimicrob Agents Chemother Date: 2000-06 Impact factor: 5.191

8. In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States.

Authors: Michael Green; Coburn Allen; John Bradley; Barry Dashefsky; Janet R Gilsdorf; Mario J Marcon; Gordon E Schutze; Clay Smith; Emmanuel Walter; Judith M Martin; Kathryn A Edwards; Karen A Barbadora; Renee M Rumbaugh; Ellen R Wald
Journal: Antimicrob Agents Chemother Date: 2005-06 Impact factor: 5.191

9. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.

Authors: K Nagai; T A Davies; L M Ednie; A Bryskier; E Palavecino; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2001-11 Impact factor: 5.191

10. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.

Authors: A L Barry; P C Fuchs; S D Brown
Journal: Antimicrob Agents Chemother Date: 1998-08 Impact factor: 5.191

10 in total